Conference abstractPublished 23 Nov 2012
Regulatory strategy for similar biologics in India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The objective of this paper is to provide guidelines to applicants to enable them to understand and comply with the regulatory requirements for the authorization of similar biologics in India. The CDSCO is the national regulatory authority in India that evaluates safety, efficacy and quality of drugs in the country. The DBT through Review Committee on Genetic Manipulation (RCGM) is responsible for overseeing the development and preclinical evaluation of recombinant biologics. There are several such products under development in India, both regulatory agencies considered the need to publish a clear regulatory pathway outlining the requirements to ensure comparable safety, efficacy and quality of a similar biologic to an authorized reference biologic. A similar biologic may require reduced preclinical and clinical data package as part of submission for market authorization. The similar biologics are regulated as per the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945 (as amended from time to time) and Rules for the manufacture, use, import, export and storage of hazardous microorganisms/genetically engineered organisms or cells, 1989 (Rules, 1989) notified under the Environment (Protection) Act, 1986. Various applicable guidelines are Recombinant DNA safety guidelines, 1990 guidelines for generating preclinical and clinical data for rDNA vaccines, diagnostics and other biological, 1999, cdsco guidance for industry. Competent authorities involved in the approval process are Review committee on genetic manipulation (RCGM) genetic engineering appraisal committee (GEAC) Central Drugs Standard control Organisation (CDSCO). Thus all the global pharmaceutical companies should follow up the guidelines approved for biologics by CDSCO for marketing authorisation in India.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Katla Sirisha”
- BylineArticles whose byline prints “T.M. Pamod Kumar”
